MedTrace Logo

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

NCT04203485 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 762

Last updated 2020-05-08

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.

Conditions

  • PD-L1 Positive Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

Camrelizumab 200mg

Camrelizumab 200mg q2w ivgtt

DRUG

Apatinib Mesylate 250mg

Apatinib Mesylate 250mg po qd

DRUG

Pemetrexed disodium for injection

Pemetrexed disodium for injection 500 mg/m2 q3w

DRUG

Paclitaxel injection

Paclitaxel injection 175 mg/m2 q3w

DRUG

Carboplatin

Carboplatin AUC 5 mg/mL/min q3w

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2022-03-31
Completion
2022-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203485 on ClinicalTrials.gov